Product Description
NPC-21 (EV2038) is a fully human monoclonal antibody that targets the antigenic domain 1 of glycoprotein B on the human cytomegalovirus (hCMV) envelope. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34989174/)
Mechanisms of Action: AD-1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nobelpharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cytomegalovirus Infections|Kidney Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2041200019 | P2 |
Active, not recruiting |
Kidney Transplant |
2023-02-28 |
|
| NPC-21-2 | P2 |
Completed |
Cytomegalovirus Infections |
2022-11-02 |
24% |